XML 106 R60.htm IDEA: XBRL DOCUMENT v3.25.1

Significant events for the years ended December 31, 2022, 2023 and 2024 and subsequent events - For the year ended 2022 (Details) € / shares in Units, € in Thousands, $ in Millions								1 Months Ended		6 Months Ended	8 Months Ended	12 Months Ended				121 Months Ended
	Oct. 24, 2023 EUR (€) € / shares shares	Oct. 24, 2023 USD ($) shares	Feb. 22, 2023 € / shares shares	Oct. 11, 2022 EUR (€)	Sep. 07, 2022 € / shares shares	Sep. 02, 2022 EUR (€) transaction € / shares shares	Dec. 01, 2021 EUR (€)	Feb. 23, 2024 EUR (€)	Aug. 31, 2022 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 12, 2022	Dec. 31, 2024 EUR (€) € / shares	Dec. 31, 2023 EUR (€) € / shares shares	Dec. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2023 EUR (€) € / shares	Nov. 19, 2024 € / shares	May 24, 2023 € / shares	Apr. 01, 2022 EUR (€)	Nov. 25, 2021 EUR (€)
Disclosure of detailed information about borrowings [line items]
Cash advances and loans made to (reimbursed from) hospitals												€ 0	€ 0	€ (3,302)
Capital increases	€ 223,300	$ 235.8										€ 0	€ 353,377	€ 46,231		€ 557,200
Capital increase from issuance of ordinary shares (in shares) | shares	20,325,500	20,325,500	20,000,000		5,530,000								40,325,500	5,530,000
Par value per share (in euro per share) | € / shares	€ 0.01		€ 0.01		€ 0.01							€ 0.01	€ 0.01	€ 0.01		€ 0.01	€ 0.01	€ 0.01
Equity issuance, subscripion price per share (in euro per share) | € / shares			€ 6.50		€ 8.36
Net proceeds from sale of royalty certificates						€ 2,931						€ 0	€ 0	€ 2,931		€ 2,900
Royalty certificate, percentage of future sales						2.00%
Royalty certificate, maximum amount						€ 172,000
Share issue related cost													28,111	3,280
Cash advances and loans made to CRO				€ 12,187				€ 5,538		€ 1,620		231	1,620	12,187
Advances related to CRO contracts												4,929	12,172	10,471		€ 12,172
€49.2 million cross-over financing, september 2022
Disclosure of detailed information about borrowings [line items]
Financial agreement, amount						€ 49,200
Financial agreement, number of transactions | transaction						2
Capital increases						€ 46,200
Capital increase from issuance of ordinary shares (in shares) | shares						5,530,000
Par value per share (in euro per share) | € / shares						€ 0.01
Equity issuance, percentage of current share capital			89.60%			33.00%
Equity issuance, subscripion price per share (in euro per share) | € / shares						€ 8.36
Net proceeds from sale of royalty certificates						€ 2,900
Royalty certificate, percentage of future sales						2.00%
Royalty certificate, maximum amount						€ 172,000
€49.2 million cross-over financing, september 2022 | Share premium
Disclosure of detailed information about borrowings [line items]
Share issue related cost						€ 3,300
Research agreement with University Hospital Center of Nice
Disclosure of detailed information about borrowings [line items]
Cash advances and loans made to (reimbursed from) hospitals									€ (3,302)						€ 4,000
Other expenses														698
AGA 2021
Disclosure of detailed information about borrowings [line items]
Compensation expenses														1,026
Social taxes related to AGAs														205
Wittycel SAS
Disclosure of detailed information about borrowings [line items]
Impairment loss recognised in profit or loss, goodwill														13,586
Impairment												€ 0	€ 0	45
Intangible assets with indefinite useful life														€ 0
Prosynergia
Disclosure of detailed information about borrowings [line items]
Loan granted							€ 1,400
Prosynergia
Disclosure of detailed information about borrowings [line items]
Cash prepayment made in 2021																			€ 325	€ 325
Cash payment made in 2022																			2,925
Earn-out, maximum amount																			4,000
Loan granted to Prosynergia in 2021																			€ 1,400
Prosynergia
Disclosure of detailed information about borrowings [line items]
Proportion of ownership interest in subsidiary											100.00%

X

- Definition

Cash Advances And Loans Made To (Reimbursed From) Hospitals

+ References

No definition available.

+ Details

Name:	abvx_CashAdvancesAndLoansMadeToReimbursedFromHospitals
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Cash Prepayment, Assets Acquisitions

+ References

No definition available.

+ Details

Name:	abvx_CashPrepaymentAssetsAcquisitions
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Cash Transferred, Assets Acquisitions

+ References

No definition available.

+ Details

Name:	abvx_CashTransferredAssetsAcquisitions
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Earn-Out, Maximum Amount

+ References

No definition available.

+ Details

Name:	abvx_EarnOutMaximumAmount
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Equity Issuance, Percentage Of Current Share Capital

+ References

No definition available.

+ Details

Name:	abvx_EquityIssuancePercentageOfCurrentShareCapital
Namespace Prefix:	abvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Equity Issuance, Subscription Price Per Share

+ References

No definition available.

+ Details

Name:	abvx_EquityIssuanceSubscriptionPricePerShare
Namespace Prefix:	abvx_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes

+ References

No definition available.

+ Details

Name:	abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Financial Agreement, Amount

+ References

No definition available.

+ Details

Name:	abvx_FinancialAgreementAmount
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Financial Agreement, Number Of Transactions

+ References

No definition available.

+ Details

Name:	abvx_FinancialAgreementNumberOfTransactions
Namespace Prefix:	abvx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase

+ References

No definition available.

+ Details

Name:	abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease
Namespace Prefix:	abvx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Loan Granted, Assets Acquisitions

+ References

No definition available.

+ Details

Name:	abvx_LoanGrantedAssetsAcquisitions
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Net Proceeds From Sale Of Royalty Certificates

+ References

No definition available.

+ Details

Name:	abvx_NetProceedsFromSaleOfRoyaltyCertificates
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Non-Current Advances To CRO Contracts

+ References

No definition available.

+ Details

Name:	abvx_NonCurrentAdvancesToCROContracts
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Payments For Advances Made to Contract Research Organizations

+ References

No definition available.

+ Details

Name:	abvx_PaymentsForAdvancesMadeToContractResearchOrganizations
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Royalty Certificate, Maximum Amount

+ References

No definition available.

+ Details

Name:	abvx_RoyaltyCertificateMaximumAmount
Namespace Prefix:	abvx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Royalty Certificate, Percentage Of Future Sales

+ References

No definition available.

+ Details

Name:	abvx_RoyaltyCertificatePercentageOfFutureSales
Namespace Prefix:	abvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of cash advances and loans made to other parties (other than advances and loans made by a financial institution), classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_e&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_CashAdvancesAndLoansMadeToOtherPartiesClassifiedAsInvestingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2024-01-01
-Paragraph 51
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2024-01-01
-Paragraph B67
-Subparagraph d
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2024-01-01
-Paragraph 118
-Subparagraph e
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 36
-IssueDate 2024-01-01
-Paragraph 134
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_b&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 36
-IssueDate 2024-01-01
-Paragraph 135
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_b&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2024-01-01
-Paragraph 122
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The nominal value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 79
-Subparagraph a
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ParValuePerShare
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The cash inflow from issuing shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProceedsFromIssuingShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 19B
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of cost related to the issuance of shares.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 106
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ShareIssueRelatedCost
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	abvx_PrincipalAgreementsAxis=abvx_ResearchAgreementWithUniversityHospitalCenterOfNiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2021Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=abvx_ProsynergiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	abvx_AssetsAcquisitionsAxis=abvx_ProsynergiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=abvx_ProsynergiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: